Opus Genetics (IRD) Net Income towards Common Stockholders (2010 - 2026)

Opus Genetics (IRD) has 17 years of Net Income towards Common Stockholders data on file, last reported at -$65.5 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 699.79% year-over-year to -$65.5 million in Q1 2026; TTM through Mar 2026 was -$96.5 million, a 64.65% decrease from a year earlier, with the FY2025 full-year figure at -$39.2 million, up 31.9% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$65.5 million, down from -$6.1 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for IRD reached as high as $33.9 million in Q4 2022 and fell as low as -$65.5 million in Q1 2026.
• Historically, Net Income towards Common Stockholders has averaged -$9.1 million across 5 years, with a median of -$6.6 million in 2022.
• Across the five-year window, Net Income towards Common Stockholders soared 637.64% in 2022 and slumped 699.79% in 2026, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at $33.9 million in 2022, then slumped by 114.13% to -$4.8 million in 2023, then slumped by 632.74% to -$35.1 million in 2024, then soared by 82.61% to -$6.1 million in 2025, then plunged by 972.76% to -$65.5 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$65.5 million in Q1 2026, -$6.1 million in Q4 2025, and -$17.5 million in Q3 2025.